Cargando…

Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study

BACKGROUND: Fondaparinux is the first approved anticoagulant drug among factor Xa inhibitors, with proven effectiveness and safety in preventing deep vein thrombosis. However, limited data are available supporting the benefit-risk profile of fondaparinux vs enoxaparin in a real-world group of Indian...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramakrishna, Pinjala, Gupta, P. C., Pai, Paresh, Rai, Kumud, Rajkumar, M., Sahu, Tapish, Khan, Mohammed Yunus, Gaurav, Kumar, Mane, Amey, Pandit, Sucheta, Jain, Madhur, Subramaniyan, Anand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844336/ https://www.ncbi.nlm.nih.gov/pubmed/34435340 http://dx.doi.org/10.1007/s40801-021-00273-4

Ejemplares similares

Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population
por: Dalal, Jamshed, et al.
Publicado: (2022)

The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist
por: Shimizu, Kazuhiro, et al.
Publicado: (2018)

Postoperative decreased levels of D-dimer in patients with gynecologic cancer with enoxaparin and fondaparinux thromboprophylaxis
por: KODAMA, JUNICHI, et al.
Publicado: (2013)

Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa
por: Siddiqui, Fakiha, et al.
Publicado: (2020)

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data
por: Soeiro, Alexandre de Matos, et al.
Publicado: (2016)

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study
por: Cardillo, Giuseppe, et al.
Publicado: (2021)

Enoxaparin-sodium/fondaparinux-sodium: Major and clinically relevant bleeding complications: 8 case reports
Publicado: (2020)

Fondaparinux: A cornerstone drug in acute coronary syndromes
por: Khan, Mohammed Yunus, et al.
Publicado: (2022)

Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism after total hip replacement: A meta-analysis
por: Dong, Wen-Jun, et al.
Publicado: (2016)

The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin
por: Prandoni, Paolo, et al.
Publicado: (2020)

Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study
por: Russo, Vincenzo, et al.
Publicado: (2020)

Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5)
por: Alfonso Ross Terres, Jorge, et al.
Publicado: (2015)

Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia
por: Vadi, Sonali, et al.
Publicado: (2018)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients
por: Zhang, Zhi-Hao, et al.
Publicado: (2017)

Recurrent thrombosis rescued by fondaparinux in high‐risk patients: A case series
por: Tanguay, Mégane, et al.
Publicado: (2022)

Fondaparinux-associated Thrombocytopenia
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
por: Shimizu, Kazuhiro, et al.
Publicado: (2016)

Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records
por: Khan, Mohammed Yunus, et al.
Publicado: (2021)

When Will Fondaparinux Induce Thrombocytopenia?
por: Chen, Li-Yu, et al.
Publicado: (2022)

Design and Synthesis of Neutralizable Fondaparinux
por: Zhang, Liangwei, et al.
Publicado: (2022)

Effectiveness of Amlodipine on Blood Pressure Control in Hypertensive Patients in India: A Real-World, Retrospective Study from Electronic Medical Records
por: Khan, Mohammed Yunus, et al.
Publicado: (2020)

Venous thromboembolism risk & prophylaxis in the acute hospital care setting (ENDORSE), a multinational cross-sectional study: Results from the Indian subset data
por: Pinjala, Ramakrishna
Publicado: (2012)

Use of Fondaparinux Following Elective Lumbar Spine Surgery Is Associated With a Reduction in Symptomatic Venous Thromboembolism
por: Fourman, Mitchell S., et al.
Publicado: (2019)

Comparison of Enoxaparin and Rivaroxaban in the Prophylaxis of Deep Venous Thrombosis in Arthroplasty
por: Çiçek, Necati, et al.
Publicado: (2021)

Anticoagulant therapy with fondaparinux in a liver transplant patient with thrombosis and liver fibrosis: a case report
por: Cafolla, Arturo, et al.
Publicado: (2017)

Efficacy and risks of fondaparinux 7.5 mg for deep vein thrombosis after total knee arthroplasty
por: Nojiri, Sho, et al.
Publicado: (2019)

Management of acute coronary syndromes with fondaparinux
por: Wienbergen, Harm, et al.
Publicado: (2007)

Thromboelastographic monitoring of fondaparinux in surgical patients
por: Martinez, B, et al.
Publicado: (2013)

Electronic medical records-based retrospective, longitudinal, observational study to understand the patient management of benign prostatic hyperplasia with alpha-blockers monotherapy in Indian population
por: Gupta, Rahul, et al.
Publicado: (2023)

Efficacy and safety of bivalirudin bridging enoxaparin versus fondaparinux in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: evidence from a single-center study
por: Guo, Yanqing, et al.
Publicado: (2023)

Hyperthyroidism: A Rare Cause of Cerebral Venous Thrombosis
por: Arguinchona, Joseph, et al.
Publicado: (2021)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
por: Spyropoulos, Alex C, et al.
Publicado: (2008)

Effectiveness and Effect on Renal Parameters of Amlodipine vs. Other Dihydropyridine Calcium Channel Blockers in Patients with Essential Hypertension: Retrospective Observational Study Based on Real-World Evidence from Electronic Medical Records
por: Jadhav, Uday, et al.
Publicado: (2021)

Failure of Fondaparinux in Autoimmune Heparin-Induced Thrombocytopenia
por: Sartori, Michelangelo, et al.
Publicado: (2020)

Probable fondaparinux-associated bullous hemorrhagic dermatosis
por: Lovatt, Catherine Anne, et al.
Publicado: (2021)

Efficacy and safety of enoxaparin as deep vein thrombosis prophylaxis in critically ill patients
por: Al-Hubail, R, et al.
Publicado: (2012)

A Retrospective, Observational, EMR-Based Real-World Evidence Study to Assess the Incidence of Pedal Edema in Essential Hypertensive Patients on Amlodipine or Cilnidipine
por: Dalal, Jamshed, et al.
Publicado: (2022)

Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports
por: Patel, Rahul P., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_agqkg4913e2l8s28tlrfi8m03g